Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Inclusion Criteria: * DCIS or Stage I-III primary invasive carcinoma of the breast * Primary surgical treatment is lumpectomy + SLNB or ALND --or-- mastectomy + ALND * Signed written informed consent * At least 18 years of age * ECOG performance status 0 to 2 * Life expectancy of at least 6 months * Total bilirubin ≤ 2 mg/dL * AST/SGOT and ALT/SGPT ≤ 2.5 X ULN * Negative serum pregnancy test and using medically acceptable form of contraception if of child bearing potential * LVEF within normal limits if patient received prior anthracycline therapy \[Period 1\]. Exclusion Criteria: * Recurrent ipsilateral breast cancer * Prior neoadjuvant chemotherapy, endocrine therapy, or biologic therapy for current breast cancer \[Period 2\] * Prior neoadjuvant chemo or biologic therapy for current breast cancer within 4 weeks prior to planned surgery \[Period 1\] * Open surgery in ipsilateral breast within 1 year. * Prior malignancy, other than breast cancer, active within the last 6 months * Prior radiation therapy to the chest \[Period 2\] * Radiation therapy to ipsilateral breast \[Period 1\] * Abnormal cardiac rhythm not controlled with medication; Hx of stroke within 1 year; Hx of coronary events and/or heart failure within 1 year. * Diagnosis of autoimmune disorder, including RA, SLE, or Sjogren's syndrome * Hx of drug-related anaphylactic reactions, severe allergic reactions related to drug; active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma re…